• Test Code:
    5005
  • Department:
    Solid Tumors
  • Test Synonyms:
    MGMT
  • CPT Code(s):
    81287
Background:

O6-methylguanine methyltransferase (MGMT) gene encodes a DNA repair enzyme that de-alkylates guanines in DNA. Methylation of CpG sites in the promoter region of the MGMT gene leads to decreased expression of this enzyme, allowing accumulation of alkylguanines that, following incorrect base pairing with thymine, cause DNA damage signaling and cell death.  

MGMT promoter methylation predicts for increased sensitivity of gliomas to alkylating agents like BCNU (carmustine), and also correlates with prolonged progression-free survival in temozolomide treated patients.

Methodology:

  1. Microscopic examination of the specimen and macrodissection of tumor-rich areas.
  2. DNA extraction and purification.
  3. Bisulfite treatment of the DNA.
  4. Methylation-specific PCR for selected regions of the MGMT gene promoter region.

Specimen Requirements:

  • A paraffin block or
  • 10 unstained sections of tumor (4-5 microns)(15 sections for small biopsies). 

Contact Client Services for shipping materials and procedures at (855) 535-1522.

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

Test Performed (Days):

Mon – Fri

Turn Around Time:

7-10 calendar days

Shipment Sensitivity Requirements:

  • Keep specimen cool during transit. Do not ship on dry ice.
  • Please use the cold pack provided in the KDL shipping kit.
  • Ship the specimen overnight express, using the FedEx priority overnight label provided. 
  • Contact Client Services for shipping materials and procedures at (855) 535-1522.

References:

  1. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. British Journal of Cancer 2009;101:124-131.
  2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66.

Additional Info:

Contact Us
Innovations in Testing
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More